imofinostat

**Imofinostat** (also known as MPT0E028 or ABT-301) is a novel, orally bioavailable small molecule that acts as a dual-action inhibitor, targeting both **histone deacetylase (HDAC)** enzymes and the **Akt (protein kinase B)** signaling pathway. Developed by **Anbogen Therapeutics** in collaboration with **Taipei Medical University**, imofinostat is characterized as a pan-HDAC inhibitor with significant potency against HDAC1, HDAC2, and HDAC6. Its mechanism of action involves inhibiting the deacetylation of histones, which leads to chromatin remodeling and the reactivation of tumor suppressor genes. Uniquely, imofinostat also directly inhibits Akt phosphorylation, disrupting a critical pathway for cancer cell survival and proliferation. This dual-targeting approach is designed to enhance pro-apoptotic activity and overcome resistance seen with single-target HDAC inhibitors. The drug has been evaluated in clinical trials for the treatment of advanced **solid tumors**, **B-cell lymphomas**, and **hepatocellular carcinoma**.

Other names

Imofinostatum(2E)-3-[1-(Benzenesulfonyl)-2,3-dihydro-1H-indol-5-yl]-N-hydroxyprop-2-enamide(E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxy-acrylamide